Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the European Commission (EC) to treat adults with ulcerative colitis (UC).

MATILDA Ahdrian had her rectum removed and her anus sewn shut to save her life – a major operation that’s been dubbed ‘Barbie Butt’. “I don’t have a bum hole anymore ...

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...

Autoimmune diseases are known for being critical to handle and treat, but today, with the advancements in modern medicines ...

Explore the complexities of Ulcerative Colitis, its causes, diagnostic methods, and breakthrough treatments for better ...

A breakdown of Crohn’s disease, its symptoms, causes, and long-term impact on health. Explore the causes, symptoms, diagnosis ...

Irritable bowel syndrome (IBS) can mimic some symptoms of inflammatory bowel disease (IBD). Learn how their causes, diagnosis ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

For anyone with ulcerative colitis (UC), remission is a beautiful word. No longer having to cope with daily painful bowel movements, stomach cramping, and discomfort gives you a lot more time to ...

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

Although the appendix is generally believed to be a vestigial organ, there is growing evidence pointing to its possible role in modulating gut immunity and microbial homoeostasis.1,2 These roles have ...